DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Filspari - 2 Vas Narasimhan - 2 atrasentan - 2 Narasimhan - 2 Kisqali - 2 Miranda Murray - 2 Kim Coghill - 2 Sonali Paul - 2
Top related locs:
U.S United States Thursday's Seattle Swiss IgAN
Top related orgs:
U.S . Food - 2 Novartis - 2 Chinook Therapeutics - 2 Sandoz - 2 Chinook - 2 Thomson - 2 Citi - 1 FDA - 1

Search resuls for: "IgAN"


4 mentions found


☆ Citi says buy this little-known biotech stock with nearly 60% upside
  + stars: | 2023-12-05 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
Battered-down biotechnology stock Travere Therapeutics could see a strong turnaround, according to Citi. Analyst Carly Kenselaar upgraded the clinical-stage company to buy/high risk and raised her price target by $3 to $10, which suggests shares could climb nearly 59% over the next 12 months. Kenselaar's new rating comes after some positive signals indicate the company is on track to obtaining full approval for its Filspari drug. "With the stock trading below cash, we believe risk/reward is skewed quite favorably into a full approval decision, supporting our upgrade," Kenselaar wrote in a Tuesday note. The move would extend its cash runway into 2028, the company said, which Kenselaar pointed to as another catalyst for her increased price target.
Persons: Carly Kenselaar, Kenselaar, Filspari, Travere Organizations: Citi, U.S . Food, FDA Locations: U.S
☆ JPMorgan says this little-known biotech company could rally 66%
  + stars: | 2023-07-21 | by ( Hakyung Kim | Https | Www.Linkedin.Com In Hakyungkim | ) www.cnbc.com   time to read: +1 min
Rare diseases treatment developer Travere Therapeutics has the potential for meaningful long-term value, according to JPMorgan. Analyst Anupam Rama initiated coverage on Travere with an overweight rating Friday. The December 2024 price target of $26 implies shares surging 66% from Thursday's close. Earlier this year, Filspari received accelerated approval from the U.S. Food and Drug Administration. The company is also awaiting regulatory feedback for pegtibatinase , which is designed to treat classical homocystinuria, a rare genetic metabolic disorder.
Persons: Anupam Rama, Filspari, Rama, — CNBC's Michael Bloom Organizations: Travere Therapeutics, JPMorgan, U.S . Food, Drug Administration Locations: Thursday's, U.S
☆ Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease
  + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
June 12 (Reuters) - Novartis (NOVN.S) said it has agreed to acquire U.S. biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment. The other drug hopeful is iptacopan, which is being trialled against a number of rare genetic disorders, including IgAN and another kidney disease. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to kidney failure that requires dialysis or organ transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, Novartis added. Additional reporting by Miranda Murray; Editing by Kim Coghill, Sonali Paul and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.
Persons: Novartis, Vas Narasimhan, Narasimham, atrasentan, Narasimhan, Kisqali, Roche, Vera, Muddy Waters, Miranda Murray, Kim Coghill, Sonali Paul, Alexander Smith Organizations: Novartis, Chinook Therapeutics, Vera Therapeutics, Sandoz, Chinook, Thomson Locations: Seattle, United States
☆ Novartis to buy Chinook for up to $3.5 bln in boost to late-stage pipeline
  + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
June 12 (Reuters) - Novartis (NOVN.S) has agreed to acquire Seattle-based biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease. Chinook is also working on zigakibart, another experimental IgAN treatment that is injected, and plans to start a Phase 3 trial in the third quarter of 2023. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to dialysis or kidney transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, the company added. Additional reporting by Miranda Murray; Editing by Kim Coghill and Sonali PaulOur Standards: The Thomson Reuters Trust Principles.
Persons: Swiss drugmaker, Vas Narasimhan, atrasentan, Narasimhan, Kisqali, Soliris, Miranda Murray, Kim Coghill, Sonali Paul Organizations: Novartis, Seattle, Chinook Therapeutics, Chinook, Swiss pharma, Sandoz, Thomson Locations: Swiss, IgAN, United States
0 next >>
Total: 4